NewsSource: EClinCloud

[Invitation] EClinCloud Invites You to the September 2 Salon on Drug Clinical Trial Development Experience and Skills

3 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.


Salon on Drug Clinical Trial Development Experience and Skills

Article image

As China's biopharmaceutical sector accelerates into a new phase centered on innovative R&D, the number of drugs advancing from the laboratory to the clinic is surging. Unlike generic drug development, which follows an established path, clinical trials for innovative drugs involve far more exploration without a clear precedent. Accordingly, improving the skills of biopharmaceutical clinical trial practitioners is essential to addressing one of the key bottlenecks in accelerating the market entry of innovative drugs.


On September 2, 2022, the Salon on Drug Clinical Trial Development Experience and Skills will be held in Chengdu. Dr. Qin Long, CEO of EClinCloud, will join industry experts to discuss the many challenges facing clinical trials for innovative drugs across areas including trial design, biostatistical analysis, and clinical trial big data, aiming to present attendees with a complete picture of clinical trial experience and help practitioners enhance their skills.

(Attendance for this salon is limited to 80 participants)


Hosts:

Chengdu Tianhe Traditional Chinese and Western Medicine Technology Incubation Co., Ltd.

Sichuan Provincial Science and Technology Resource Sharing Service Platform for Pharmaceutical R&D Technological Innovation

 

Co-Host:

Chengdu Hi-Tech Investment Biomedical Park Management Co., Ltd.

 

Supporting Organizations:

Chengdu Fanweixi Pharmaceutical Technology Co., Ltd.

Chengdu Xingpulai Data Analysis Co., Ltd.

Chengdu Yaoyouzhijia Pharmaceutical Technology Co., Ltd.

Chengdu Saimeisi Medical Technology Co., Ltd.

Chengdu Qisheng Heyan Pharmaceutical Technology Co., Ltd.

Chongqing Yaoda Big Data Co., Ltd.

Boji Medical Technology Co., Ltd.

Jiangsu Lihua Biotechnology Co., Ltd.

Inner Mongolia Jingdong Pharmaceutical Co., Ltd.

Ya'an Xunkang Pharmaceutical Co., Ltd.

EClinCloud (Shenzhen) Technology Co., Ltd.

Yaorongquan, Xiangrong (Shanghai) Biotechnology Co., Ltd.

Guest Speakers

Article image


Jiang Xuehua

President, Sichuan Pharmaceutical Association

Former Professor and Doctoral Advisor, West China School of Pharmacy, Sichuan University

Former Chair, Department of Clinical Pharmacy and Pharmacy Administration, and Former Director, Clinical Pharmacy Research Center, West China School of Pharmacy, Sichuan University


Presentation Topic: "Bioequivalence Evaluation of Endogenous Drugs"

Article image


Liang Maozhi

Researcher, Department of Clinical Research Management

Vice Chair, Clinical Trial Ethics Committee, West China Hospital

Vice Chair, Biomedical Ethics Committee, West China Hospital


Presentation Topic: "Discussion on Selected Issues in Designing Clinical Trial Development Pathways for Innovative Drugs"

Article image

Qin Long

CEO, EClinCloud (Shenzhen) Technology Co., Ltd.

With over 16 years of experience in technology applications for the clinical research industry, he is a pioneer in promoting and implementing technical solutions such as eCOA, EDC, CTMS, and Argus in China's clinical trial research field.


Presentation Topic: "Scale and Rating Management in Clinical Research"

Article image

Zhu Yanfei

General Manager, Boyi Fund

Presentation Topic: "Biopharmaceutical Investment Opportunities and Responses in the New Environment"

Article image

Li Xiaopeng

General Manager, Chengdu Xingpulai Data Analysis Co., Ltd.

Presentation Topic: "How Biostatistics Supports Clinical Research"

Article image

Tang Xuewen

Co-Founder, Chongqing Yaoda Big Data Co., Ltd.

Presentation Topic: "Insights into China's New Drug Development Competitive Landscape Through Clinical Trial Big Data"

Event Information


Event Time:

September 2, 2022, 13:30–18:30

(Check-in begins at 13:00)

 

Event Venue:

Hejisheng Conference Room, Floor 1, Building A, Building 1 (Tianhe Incubator Park), No. 1480 North Section of Tianfu Avenue, Chengdu Hi-Tech Zone


Scan the QR Code to Register:

Article image


About EClinCloud


EClinCloud provides an integrated, unified cloud platform (including solutions such as CTMS, eTMF, EDC, RTSM, eCOA, and eConsent and consulting services such as scale management, linguistic validation, rater training, study build and configuration, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including oncology, neurology, cardiology, pulmonology, and dermatology). Combining cutting-edge technology with life sciences data, EClinCloud is building a globally leading "patient-centric" SaaS cloud platform supporting clinical evidence to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article image


Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.